ADVANCED DERMATOTHERAPEUTICS

SL. No.

Particulars in Field

Inputs

1

Event Name

ADVANCED DERMATOTHERAPEUTICS

2

Organizing Department/Institution/Committee/Others

Department of Dermatology ,JSS Medical college, JSSAHER, Mysore

3

Type of Event

 CME

4

Level of Event

State level

5

Collaboration/Accreditation of any

IADVL Karnataka

6

Date/s and Duration

12^th July,2026

7

Venue

SRCA,3rd Floor, JSS Hospital, MG Road, Mysore

8

Details of delegates/ target audience

Dermatology faculty and Dermatology post graduates

9

Total Number of delegates/audience attended

Postgraduates

1) Dr. Balijepalli Sai Vamsi – 3^rd Year PG

2) Dr. Jayaprakash – 3^rd Year PG

3) Dr. Jithin Jayraj – 3^rd Year PG

4) Dr. Harshini J – 3^rd Year PG

5) Dr. Lakshmi GN – 3^rd Year PG

6) Dr. Nisarga Yoganand -2^nd Year PG

7) Dr. Rakshith D -2^nd Year PG

8) Dr. Ranjeeta S Chauwan -2^nd Year PG

9) Dr. Amogh N Goure -1^st  Year PG

10) Dr .Shifali Harinath -1^st  Year PG

11) Dr .Swathi M V-1^st  Year PG

10

Objective/s of the Event

1) Enhance Knowledge of Immune-Mediated Dermatological Disorders

• Update participants on the current concepts in the diagnosis, pathogenesis, and management of immunobullous and papulosquamous disorders.

2) Promote Evidence-Based Therapeutics

• Discuss recent clinical evidence, treatment guidelines, and best practices for managing chronic inflammatory skin diseases.

3) Introduce Emerging Immunomodulatory Therapies

• Familiarize participants with oral JAK inhibitors, newer topical immunomodulators, biologics, and evolving treatment strategies in dermatology.

5) Understand the Role of Older and Repurposed Drugs

• Review the continued relevance of conventional therapies and repurposed medications in the era of biologics and targeted treatments.

6) Explore Novel Therapeutic Advances

• Highlight emerging concepts such as microbiome-based therapies and innovative treatment approaches with potential clinical applications.

6) Encourage Interactive Clinical Learning

•Facilitate case-based discussions and expert panel interactions to improve clinical reasoning and decision-making in difficult dermatological conditions.

7) Strengthen Clinical Decision-Making

•Enable participants to individualize treatment plans by balancing efficacy, safety, accessibility, and patient-specific factors.

8) Support Continuing Medical Education

•Encourage lifelong learning, interdisciplinary collaboration, and professional development through expert-led scientific sessions and academic exchange.

11

Brief Report of the Event (in about 200 words)

Postgraduates presented the following papers in the conference:

PG:

12

Achievements

Dr  Rakshith D, 2^nd  year PG

 secured  2^nd place for the paper “Effect of oral tofacitinib on trachyonychia; A single case  report”

13

Feedback Analysis (Brief)

1.     Scientific Sessions: Participants appreciated the evidence-based lectures on immunobullous disorders, papulosquamous disorders, JAK inhibitors, microbiome-based therapies, and newer immunomodulators, which were highly relevant to current dermatology practice.

2.      Panel Discussions: Interactive panel discussions on vesiculobullous and papulosquamous disorders were well received, providing practical insights into challenging clinical scenarios and encouraging active audience participation.

3.     Clinical Relevance: Delegates valued the emphasis on emerging therapies, repurposed drugs, and therapeutic updates that could be readily incorporated into day-to-day patient management.

4.      Paper Presentation: The postgraduate paper presentation session was appreciated for promoting scientific research, critical thinking, and academic interaction among young dermatologists.

5.      Organization: Participants commended the smooth coordination, time management, and overall execution of the CME programme.

6.      Scope for Improvement: A few attendees suggested allocating more time for audience interaction, case-based discussions, and question-and-answer sessions to facilitate deeper learning.

14

Outcome:

1.     Enhanced knowledge of the latest evidence-based approaches in the diagnosis and management of immunobullous and papulosquamous disorders.

2.      Improved understanding of emerging therapeutic options, including JAK inhibitors, newer topical immunomodulators, microbiome-based therapies, and repurposed drugs.

3.      Strengthened clinical decision-making through expert lectures and interactive panel discussions addressing complex dermatological conditions.

4.      Increased awareness of recent advances in therapeutics, enabling participants to deliver more effective and patient-centred care.

5.     Encouraged scientific thinking and research aptitude through postgraduate paper presentations and academic discussions.

6.      Promoted interdisciplinary learning, networking, and collaboration among dermatologists, academicians, and postgraduate students.

7.      Reinforced the importance of Continuing Medical Education (CME) in keeping clinicians updated with evolving treatment guidelines and innovations in dermatology.

8.      Enhanced confidence in applying current evidence and newer therapeutic strategies in routine dermatology practice.

15

SDG addressed

1)SDG 3: Good Health and Well-Being

2) SDG 4: Quality Education

3) SDG 9:  Industry, Innovation and Infrastructure

4) SDG 17: Partnerships for the Goals

16.

Challenges faced

        NIL

17.

Recommendations

        NIL